Epidemiology of Acromegaly in Denmark 1991-2010

Status Active, not recruiting

Clinical Trial Summary

Aim: To assess the incidence rate, morbidity and mortality of acromegaly in Denmark.

Clinical Trial Description

Background: Acromegaly is a rare disease caused by GH hypersecretion from a pituitary adenoma. The annual incidence is estimated to be 3-5/million with a prevalence of 100 - 150/million. The incidence rate is however uncertain since no nationwide surveys exist. If left untreated or poorly controlled the condition is associated with progressive morbidity and an excess mortality. The primary treatment is surgery, which however only provides a cure rate of ≈ 50 -60% due to the size of the tumour. The second line treatment today is medical treatment with slow release formulations of somatostatin analogs (SA) and, more recently, a specific GH antagonist.

Accurate data on incidence rates and outcome of treatment are of obvious importance in order to provide optimal and evidence-based treatment for the disease. This is particularly relevant in light of the availability of new and effective treatment modalities such as the GH antagonist, the proper place of which in the treatment algorithm still remains controversial.

Denmark holds a unique position in terms of epidemiological studies due to the existence of well organized databases which include all its inhabitants. A recognised problem with epidemiological surveys from specialised centres is whether the figures are representative for the general population. A nationwide Danish study will profit from the fact that every Danish citizen holds a unique ID number that makes it easy to retrieve and combine pertinent data regarding health, disease and death from different registries. The investigators have previously used this for a landmark survey of another rare endocrine disease, i.e. Cushing's syndrome. This publication has been cited more than 100 times.

Aim: To assess the incidence rate, morbidity and mortality of acromegaly in Denmark. ;

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

Acromegaly

Clinical Trial Details

NCT number	NCT01752621
Study type	Observational
Source	University of Aarhus
Contact
Status	Active, not recruiting
Phase	N/A
Start date	February 2013
Completion date	March 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06344650` - Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
Active, not recruiting	`NCT02092129` - Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.	N/A
Completed	`NCT02012127` - Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
Active, not recruiting	`NCT01265121` - Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.	N/A
Terminated	`NCT00765323` - Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly	Phase 3
Completed	`NCT00500227` - Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
Completed	`NCT00531908` - Physiopathology of Sodium Retention in Acromegaly	N/A
Completed	`NCT01278342` - Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients	Phase 4
Active, not recruiting	`NCT01809808` - A Prospective Study of Outcome After Therapy for Acromegaly
Completed	`NCT00145405` - Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction	Phase 4
Completed	`NCT00210457` - Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients	Phase 3
Recruiting	`NCT05401084` - Diet in the Management of Acromegaly	N/A
Recruiting	`NCT00005100` - Measurement of Outcome of Surgical Treatment in Patients With Acromegaly	N/A
Completed	`NCT00521300` - Preoperative Octreotide Treatment of Acromegaly	Phase 4
Completed	`NCT03548415` - Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands	Phase 2
Not yet recruiting	`NCT04066569` - Reproducibility and Utility of OGTT in Acromegaly	N/A
Not yet recruiting	`NCT05298891` - Hypoproteic Diet in Acromegaly	N/A
Recruiting	`NCT04520646` - A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy	N/A
Not yet recruiting	`NCT04529356` - The TMS Treatment for Postoperative Headache in GH Tumor	N/A
Active, not recruiting	`NCT03252353` - Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly	Phase 3